TROG 99.02 - Anal Canal - TROG Cancer Research

By w.paterson
14 August, 2021
0 Comments

A Prospective Single Arm Non Randomised Study of Concurrent Radiation and Chemotherapy For the Organ Conserving Treatment of Early Anal Canal Cancer

Primary Sponsor

13 November, 2024

Trek4TROG team rise to Blue Mountains challenge

November 2024: Congratulations to the Trek4TROG team for successfully

24 October, 2024

Promising new results from RAIDER trial published

24 October 2024: Newly published findings from the TROG

Register for the 2025 ASM

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Prospective Single Arm Non Randomised Study of Concurrent Radiation and Chemotherapy For the Organ Conserving Treatment of Early Anal Canal Cancer

TROG 99.04/ALLG LY02 – Osteolymphoma – OL

ANZLG HD3/TROG 99.01 – Hodgkins Disease IFRT – HD3

Related Post

Trek4TROG team rise to Blue Mountains challenge

Promising new results from RAIDER trial published

Register for the 2025 ASM

TROG 99.02 – Anal Canal

A Prospective Single Arm Non Randomised Study of Concurrent Radiation and Chemotherapy For the Organ Conserving Treatment of Early Anal Canal Cancer

TROG 99.04/ALLG LY02 – Osteolymphoma – OL

ANZLG HD3/TROG 99.01 – Hodgkins Disease IFRT – HD3

Related Post

Trek4TROG team rise to Blue Mountains challenge

Promising new results from RAIDER trial published

Register for the 2025 ASM